Teva draws blank in phase 3 Tourette Syndrome trialTeva’s late stage trials of a potential drug for Tourette Syndrome have drawn a blank, just when the Share XTeva draws blank in phase 3 Tourette Syndrome trialhttps://pharmaphorum.com/news/teva-draws-blank-in-phase-3-tourette-syndrome-trial/
Gilead poaches oncology expert Quigley from BMSGilead has poached an oncology research leader from Bristol-Myers Squibb, appointing Michael Quigley as senior vice president of Share XGilead poaches oncology expert Quigley from BMShttps://pharmaphorum.com/news/gilead-poaches-oncology-expert-quigley-from-bms/
GW Pharma tops list of UK R&D spendersPharma is leading the way in R&D investment in the UK, with cannabis medicine specialist GW splurging almost Share XGW Pharma tops list of UK R&D spendershttps://pharmaphorum.com/news/pharma-leads-rd-investment-in-uk/
Sanofi Pasteur to develop COVID-19 vaccine with US governmentSanofi Pasteur, the global vaccines business unit of the French drug maker Sanofi, has joined forces with a Share XSanofi Pasteur to develop COVID-19 vaccine with US governmenthttps://pharmaphorum.com/news/sanofi-pasteur-to-develop-covid-19-vaccine-with-us-government/
UK biotech OMass raises £27.5m for GPCR drug discoveryOxford, UK-based OMass Therapeutics has extended its first-round financing to more than £41 million ($53 million), to help Share XUK biotech OMass raises £27.5m for GPCR drug discoveryhttps://pharmaphorum.com/news/uk-biotech-omass-raises-27-5m-for-gpcr-drug-discovery/
Castor gifts access to data platform for non-profit Covid-19 researchHealth tech company Castor has said it will provide free access to its electronic data capture (EDC) systems Share XCastor gifts access to data platform for non-profit Covid-19 researchhttps://pharmaphorum.com/news/castor-gifts-access-to-data-platform-for-non-profit-covid-19-research/
Chiesi starts rare diseases division, ahead of potential Fabry disease filingItalian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch Share XChiesi starts rare diseases division, ahead of potential Fabry disease filinghttps://pharmaphorum.com/news/chiesi-starts-rare-diseases-division-as-fabry-treatment/
Blockbusters in waiting: drug launches to watch in 2020New drugs for breast cancer, lymphoma, multiple sclerosis and migraine are among new product launches this year that Share XBlockbusters in waiting: drug launches to watch in 2020https://pharmaphorum.com/news/blockbusters-in-waiting-drug-launches-to-watch-in-2020/
Janssen trials ultrasound-guided approach to treating Crohn’sIn the highly competitive market for inflammatory diseases such as Crohn’s, pharma companies are looking for ways to Share XJanssen trials ultrasound-guided approach to treating Crohn’shttps://pharmaphorum.com/news/janssen-trials-ultrasound-guided-approach-to-treating-crohns/
Futura seeks EU approval of erectile dysfunction gel as medical deviceUK biotech Futura Medical has said it will seek approval for its MED3000 topical treatment for erectile dysfunction Share XFutura seeks EU approval of erectile dysfunction gel as medical devicehttps://pharmaphorum.com/news/futura-seeks-eu-approval-of-erectile-dysfunction-gel-as-medical-device/
J&J strengthens R&D into COVID-19 vaccine with US governmentJohnson & Johnson has announced it has expanded a collaboration with a US government agency to hasten development Share XJ&J strengthens R&D into COVID-19 vaccine with US governmenthttps://pharmaphorum.com/news/jj-strengthens-rd-into-covid-19-vaccine-with-us-government/
Novartis plots cardio trial in UK as London HQ opensNovartis has announced the beginnings of a major cardiovascular outcomes trial in the UK, as it opened a Share XNovartis plots cardio trial in UK as London HQ openshttps://pharmaphorum.com/news/novartis-plots-cardio-trial-in-uk-as-london-hq-opens/
Roche and Lilly’s Alzheimer’s drugs draw blanks in inherited diseaseAs Biogen prepares for an FDA review of its amyloid-targeting Alzheimer’s drug aducanumab, Roche and Eli Lilly lifted Share XRoche and Lilly’s Alzheimer’s drugs draw blanks in inherited diseasehttps://pharmaphorum.com/news/roche-and-lillys-alzheimers-drugs-draw-blanks-in-inherited-disease/
Roche’s SMA drug risdiplam hits targets in children ahead of FDA decisionIt’s not far off crunch time for Roche’s potential spinal muscular atrophy (SMA) drug, risdiplam, which the big Share XRoche’s SMA drug risdiplam hits targets in children ahead of FDA decisionhttps://pharmaphorum.com/news/roches-sma-drug/
Wuhan Institute asks for patent on Gilead’s potential coronavirus drugA state-run research institute in China has applied for a patent on the use of Gilead’s experimental antiviral Share XWuhan Institute asks for patent on Gilead’s potential coronavirus drughttps://pharmaphorum.com/news/gilead/
BMS, BioMotiv alliance generates biopharma company AnterosA partnership between Bristol-Myers Squibb and drug development accelerator BioMotiv has yielded its first fruit just a few Share XBMS, BioMotiv alliance generates biopharma company Anteroshttps://pharmaphorum.com/news/bms-biomotiv-alliance-generates-biopharma-company-anteros/
Dutch biotech sector feel benefits of EMA move, says industry leaderThe Netherlands’ biotech sector has already seen an upswing following the relocation of the European Medicines Agency (EMA) Share XDutch biotech sector feel benefits of EMA move, says industry leaderhttps://pharmaphorum.com/news/dutch-biotech-feeling-benefits-of-ema-relocation-says-industry-leader/
GSK donates booster technology to coronavirus vaccine effortGlaxoSmithKline has joined with the not-for-profit organisation the Coalition for Epidemic Preparedness Innovations (CEPI) to supply a booster Share XGSK donates booster technology to coronavirus vaccine efforthttps://pharmaphorum.com/news/gsk-donates-booster-technology-to-coronavirus-vaccine-effort/
